03:44 PM EST - Oncolytics Biotech Inc. : announced a poster presentation covering positive preliminary results from a Phase I study examining the intravenous administration of REOLYSIN in combination with FOLFIRI in patients with metastatic colorectal cancer (REO 022). The results were presented at the ASCO Gastrointestinal Cancers Symposium in San Francisco over the weekend. Oncolytics Biotech Inc.
shares T.ONC are trading up $0.63 at $60.31.
